Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

10.41USD
21 Aug 2018
Change (% chg)

$0.09 (+0.87%)
Prev Close
$10.32
Open
$10.36
Day's High
$10.44
Day's Low
$10.25
Volume
138,338
Avg. Vol
195,503
52-wk High
$15.15
52-wk Low
$7.68

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $1,100.08
Shares Outstanding(Mil.): 105.88
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 98.72 30.39
EPS (TTM): -1.32 -- --
ROI: -58.05 0.92 12.61
ROE: -276.33 -0.89 14.80

BRIEF-Lexicon Pharmaceuticals Reports Q1 Loss Per Share $0.40

* LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

03 May 2018

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes

* LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES

26 Mar 2018

BRIEF-Lexicon Pharmaceuticals Q4 Loss Per Share $0.27

* LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

22 Feb 2018

Competitors

Earnings vs. Estimates